Why the study?
Flow-mediated dilation is operator-dependent and variable, whereas existing circulating biomarkers often fail to provide consistent information about the endothelium when measured alone.
Novel circulating biomarkers such as endothelial microparticles, endocan, and endoglin are being explored as potential clinical alternatives to flow-mediated dilation for evaluating endothelial dysfunction and stratifying cardiovascular risk.
These biomarkers may simplify endothelial assessment beyond FMD; leaves open prospective validation for cardiovascular risk stratification.
Endothelial dysfunction is one of the earliest indicators of cardiovascular (CV) dysfunction, and its evaluation would be of considerable importance to stratify CV risk of many diseases and to assess the efficacy of atheroprotective treatments. Flow-mediated dilation is the most widely used method to study endothelial function. However, it is operator-dependent and can be influenced by physiological variations. Circulating biomarkers are a promising alternative. Due to the complexity of endothelial function, many of the biomarkers studied do not provide consistent information about the endothelium when measured alone. New circulating markers are being explored and some of them are thought to be suitable for the clinical setting. In this review, we focus on novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin, and discuss whether they fulfill the criteria to be applied in clinical practice.
No takes yet. Share an insight, caveat, or question.
Leite et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: